AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27383469 — intervention group
Group type: COMPARATOR
Intervention: Prescribed moderate intensity exercise (64-76% maximum heart rate)
Number of subjects: 59
Study 23975116 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood manipulation
Number of subjects: 0
Study 23975116 — intervention group
Group type: COMPARATOR
Intervention: Self-related stimuli
Number of subjects: 0
Study 22277837 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 424
Study 22277837 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (standard docetaxel or pemetrexed regimens)
Number of subjects: 424
Study 20729242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide alone (150 mg/m²/day, 7/14‐day schedule)
Number of subjects: 54
Study 20729242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus thalidomide (400 mg/day)
Number of subjects: 54
Study 20729242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus isotretinoin (100 mg/m²/day)
Number of subjects: 54
Study 20729242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus celecoxib (400 mg twice daily)
Number of subjects: 54
Study 20729242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide plus thalidomide plus isotretinoin plus celecoxib
Number of subjects: 54
Study 20729242 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (dose-dense temozolomide with cytostatic agents)
Number of subjects: 54
Study 18362587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 1000
Study 15052242 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide perfusion testing
Number of subjects: 2951
Study 15052242 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-catheterization nuclear cohort
Number of subjects: 2951
Study 11534926 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment (IMI-IMI)
Number of subjects: 18
Study 11534926 — intervention group
Group type: COMPARATOR
Intervention: Imipramine followed by placebo substitution (IMI-PBO)
Number of subjects: 18
Study 11534926 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance treatment (PBO-PBO)
Number of subjects: 18
Study 9040027 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients with ASH and CD36 deficiency
Number of subjects: 47
Study 9040027 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM patients with CD36 deficiency
Number of subjects: 47
Study 9040027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-overload hypertrophy patients with CD36 deficiency
Number of subjects: 47
Study 9040027 — intervention group
Group type: COMPARATOR
Intervention: HCM patients without ASH
Number of subjects: 47
Study 9040027 — intervention group
Group type: EXPERIMENTAL
Intervention: Other HCM patients with ASH and CD36 deficiency
Number of subjects: 47
Study 8572058 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion product otoacoustic emissions (DPOEs) testing in elderly subjects
Number of subjects: 71
Study 3065737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 400 mg/kg body weight every 3 weeks for a year
Number of subjects: 84
Study 3065737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 84
Study 29794557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg bid)
Number of subjects: 19
Study 29794557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28760211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up via telemonitoring using an implantable cardiac monitor (ICM) device
Number of subjects: 1600
Study 28760211 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 1600
Study 26226287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 18
Study 26226287 — intervention group
Group type: COMPARATOR
Intervention: Sleep Control
Number of subjects: 18
Study 23532241 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily) for 12 months
Number of subjects: 83
Study 23532241 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 83
Study 23532241 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg daily)
Number of subjects: 83
Study 23532241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21462730 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidly obese adults
Number of subjects: 457
Study 21462730 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 457
Study 18433945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate ingestion (30 mg/kg BW)
Number of subjects: 26
Study 18433945 — intervention group
Group type: COMPARATOR
Intervention: Control ingestion (1.25 ml/kg BW)
Number of subjects: 26
Study 18433945 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate ingestion
Number of subjects: 26
Study 18433945 — intervention group
Group type: COMPARATOR
Intervention: Control ingestion
Number of subjects: 26
Study 16784930 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 69
Study 16784930 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 69
Study 16784930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 14501096 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-faceted injury prevention program (4 hours of individualized training)
Number of subjects: 16
Study 14501096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 10718783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 8 days
Number of subjects: 25
Study 10718783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9361339 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐chlorophenylpiperazine (mCPP)
Number of subjects: 18
Study 9361339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1530533 — intervention group
Group type: EXPERIMENTAL
Intervention: MATCOP
Number of subjects: 80
Study 1530533 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 80
Study 3886340 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg orally each morning)
Number of subjects: 184
Study 3886340 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg orally twice daily)
Number of subjects: 184
Study 31041425 — intervention group
Group type: EXPERIMENTAL
Intervention: Hope intervention (3 sessions)
Number of subjects: 29
Study 31041425 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (EDU)
Number of subjects: 29
Study 30107279 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 266
Study 30107279 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal exposure
Number of subjects: 266
Study 30107279 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 266
Study 26459316 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventure intervention
Number of subjects: 699
Study 24238943 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL
Number of subjects: 0
Study 24238943 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic IOL
Number of subjects: 0
Study 24238943 — intervention group
Group type: EXPERIMENTAL
Intervention: HSM PMMA IOL
Number of subjects: 0
Study 22057829 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 10 ppm followed by sildenafil 100 mg orally 30 minutes later
Number of subjects: 20
Study 22057829 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 100 mg orally followed by inhaled nitric oxide (iNO) 10 ppm 60 minutes later
Number of subjects: 20
Study 22057829 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of iNO and sildenafil
Number of subjects: 20
Study 19821509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.2 mg/kg daily
Number of subjects: 100
Study 19821509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.1 mg/kg daily
Number of subjects: 100
Study 19821509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 mg/kg daily
Number of subjects: 100
Study 19821509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19821509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.1 mg/kg daily (open-label phase)
Number of subjects: 100
Study 19821509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (all doses)
Number of subjects: 100
Study 19821509 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 100
Study 17432690 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Shiwei Tablet (CST)
Number of subjects: 459
Study 17432690 — intervention group
Group type: COMPARATOR
Intervention: Sanjin Tablet (ST)
Number of subjects: 459
Study 15367305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg as a single dose)
Number of subjects: 27
Study 15367305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 27
Study 11255905 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of an income question in the survey
Number of subjects: 0
Study 11255905 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking consent to access medical records
Number of subjects: 0
Study 11255905 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 0
Study 9676354 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained release theophylline microcapsules (T1)
Number of subjects: 0
Study 9676354 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained release theophylline microcapsules (T2)
Number of subjects: 0
Study 9676354 — intervention group
Group type: COMPARATOR
Intervention: Pellet formulation (R)
Number of subjects: 0
Study 8047519 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education interventions
Number of subjects: 501
Study 8047519 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived self‐efficacy
Number of subjects: 501
Study 8047519 — intervention group
Group type: EXPERIMENTAL
Intervention: Salience and coherence of testing
Number of subjects: 501
Study 8047519 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 501
Study 2926492 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic evacuation
Number of subjects: 100
Study 2926492 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 100
Study 30110020 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider apologies in the electronic health record
Number of subjects: 100
Study 29869903 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotypically aberrant MCL
Number of subjects: 158
Study 29869903 — intervention group
Group type: COMPARATOR
Intervention: Immunophenotypically typical MCL
Number of subjects: 158
Study 28644104 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (first three doses every 4 weeks)
Number of subjects: 625
Study 26148133 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose creatine supplementation (acute and chronic)
Number of subjects: 9
Study 26148133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose creatine supplementation (acute and chronic)
Number of subjects: 9
Study 26148133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study 25098088 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of injection Celfuroxime 1.5 gm at the time of induction of anaesthesia (Group A)
Number of subjects: 350
Study 25098088 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic (Group B)
Number of subjects: 350
Study 20842041 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐LMA
Number of subjects: 121
Study 20842041 — intervention group
Group type: EXPERIMENTAL
Intervention: GVL
Number of subjects: 121
Study 20842041 — intervention group
Group type: COMPARATOR
Intervention: DL
Number of subjects: 121
Study 20842041 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐LMA vs GVL
Number of subjects: 121
Study 19092349 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment (250 mg at consent, followed by 100 mg/h infusion)
Number of subjects: 100
Study 19092349 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment
Number of subjects: 100
Study 17159174 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin (75 mg) sustained release once daily for six weeks
Number of subjects: 121
Study 17159174 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for six weeks
Number of subjects: 121
Study 17159174 — intervention group
Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 121
Study 12715306 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 301
Study 15971244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie milkshake preload
Number of subjects: 64
Study 15971244 — intervention group
Group type: EXPERIMENTAL
Intervention: Food and eating-related thought suppression condition
Number of subjects: 64
Study 15971244 — intervention group
Group type: COMPARATOR
Intervention: No suppression control condition
Number of subjects: 64
Study 10353372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional integration task
Number of subjects: 0
Study 10353372 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention task
Number of subjects: 0
Study 10353372 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus integrality and separability manipulations
Number of subjects: 0
Study 7478405 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-tetrofosmin with exercise stress
Number of subjects: 297
Study 7478405 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-tetrofosmin with dobutamine stress
Number of subjects: 297
Study 7478405 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm-tetrofosmin overall
Number of subjects: 297
Study 1785237 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane group
Number of subjects: 52
Study 1785237 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 52
Study 7054760 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate, 50 mg/kg body weight
Number of subjects: 97
Study 7054760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 29052033 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based therapy (random-perturbation exercise, 13 weeks, 2 times per week, 1.5 hours per session)
Number of subjects: 40
Study 29052033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific training)
Number of subjects: 40
Study 25304999 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Tissue Welder (TW)
Number of subjects: 48
Study 25304999 — intervention group
Group type: COMPARATOR
Intervention: Monopolar Electrocautery (EC)
Number of subjects: 48
Study 23860247 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition
Number of subjects: 15
Study 23860247 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition
Number of subjects: 15
Study 21237718 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiretroviral prophylaxis (300 mg zidovudine, 150 mg lamivudine, and 400 mg lopinavir plus 100 mg ritonavir twice daily until cessation of breastfeeding, maximum 6.5 months postpartum)
Number of subjects: 882
Study 21237718 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and single-dose nevirapine (300 mg zidovudine twice daily until delivery, 600 mg zidovudine plus 200 mg nevirapine at onset of labour, and after protocol amendment, 300 mg zidovudine twice daily and 150 mg lamivudine twice daily for 1 week postpartum)
Number of subjects: 882
Study 19373709 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (once‐ or twice‐weekly for 4‐12 months)
Number of subjects: 55
Study 19373709 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 55
Study 17766660 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and docetaxel
Number of subjects: 0
Study 17766660 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (single agent)
Number of subjects: 0
Study 15468406 — intervention group
Group type: EXPERIMENTAL
Intervention: Artecoll
Number of subjects: 251
Study 15468406 — intervention group
Group type: COMPARATOR
Intervention: Collagen (control)
Number of subjects: 251
Study 11432768 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient and single cell oil supplement containing docosahexaenoic acid
Number of subjects: 55
Study 11432768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice and general lifestyle advice
Number of subjects: 55
Study 11432768 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented, inadequate-diet group
Number of subjects: 55
Study 9543281 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus 16 (RV16) inoculation
Number of subjects: 14
Study 9543281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7996818 — intervention group
Group type: EXPERIMENTAL
Intervention: New preservative-free tear substitute (Oculotect fluid sine)
Number of subjects: 59
Study 7996818 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment with artificial tears
Number of subjects: 59
Study 3055456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed nets (mosquito nets) used correctly by children
Number of subjects: 396
Study 3055456 — intervention group
Group type: COMPARATOR
Intervention: No bed nets (control group)
Number of subjects: 396
Study 30094970 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) - a predominantly organic diet high in fruit, vegetables, whole grains, and fish.
Number of subjects: 146
Study 30094970 — intervention group
Group type: COMPARATOR
Intervention: Average Danish Diet (ADD) - a diet higher in imported and processed foods.
Number of subjects: 146
Study 30094970 — intervention group
Group type: COMPARATOR
Intervention: NND vs ADD
Number of subjects: 146
Study 30094970 — intervention group
Group type: EXPERIMENTAL
Intervention: NND
Number of subjects: 146
Study 30094970 — intervention group
Group type: EXPERIMENTAL
Intervention: NND and ADD
Number of subjects: 146
Study 28750673 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroFIT program
Number of subjects: 1000
Study 26650626 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir and deleobuvir with ribavirin
Number of subjects: 362
Study 24199898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse initiated reinsertion of NGT (NIRNGT)
Number of subjects: 22
Study 24199898 — intervention group
Group type: COMPARATOR
Intervention: Standard NGT insertion protocol
Number of subjects: 22
Study 21359920 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture combined with Fluoxetine
Number of subjects: 75
Study 21359920 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine only (Control)
Number of subjects: 75
Study 21191332 — intervention group
Group type: EXPERIMENTAL
Intervention: Splat Oral Care Foam 2 in 1
Number of subjects: 0
Study 17701405 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg PO omeprazole (young subjects)
Number of subjects: 48
Study 17701405 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg IV omeprazole (young subjects)
Number of subjects: 48
Study 17701405 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg IV omeprazole (elderly subjects)
Number of subjects: 48
Study 17701405 — intervention group
Group type: EXPERIMENTAL
Intervention: HI3h after omeprazole IV
Number of subjects: 48
Study 16393158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose (150 and 300 mg/day for 2 weeks each; 450 and 600 mg/day for 4 weeks each, BID)
Number of subjects: 341
Study 16393158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose (600 mg/day BID)
Number of subjects: 341
Study 16393158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 16393158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose vs flexible dose
Number of subjects: 341
Study 16393158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin flexible dose
Number of subjects: 341
Study 16393158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin fixed dose
Number of subjects: 341
Study 12228785 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiology (EP) testing
Number of subjects: 572
Study 12228785 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 572
Study 10215096 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects observing target locations in the light
Number of subjects: 24
Study 10215096 — intervention group
Group type: COMPARATOR
Intervention: Subjects observing target LEDs in the dark
Number of subjects: 24
Study 8653534 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg per day
Number of subjects: 14
Study 8653534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2141262 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O-O2 enflurane
Number of subjects: 185
Study 2141262 — intervention group
Group type: COMPARATOR
Intervention: Air-O2 enflurane
Number of subjects: 185
Study 2141262 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (omitted in randomly chosen cases)
Number of subjects: 185
Study 2141262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (postoperatively for pain)
Number of subjects: 185
Study 220536 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (administered for six weeks starting on the day of transplantation)
Number of subjects: 0
Study 220536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 220536 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 0
Study 220536 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and antithymocyte globulin
Number of subjects: 0
Study 220536 — intervention group
Group type: COMPARATOR
Intervention: Interferon and placebo
Number of subjects: 0
Study 220536 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Number of subjects: 0